Carbamazepine Hypersensitivity — HLA allele-specific reactions causing Stevens-Johnson syndrome and toxic epidermal necrolysis, with up to 30% mortality, from the world's most prescribed anticonvulsant.
Whole genome sequencing provides complete HLA typing — covering HLA-B*15:02 (critical for Asian populations) and HLA-A*31:01 (critical for European populations) in a single result — guiding the most important prescribing decision in epilepsy pharmacogenomics.
Carbamazepine Hypersensitivity — HLA-B*15:02
Carbamazepine (Tegretol) is one of the most widely prescribed anticonvulsants for focal epilepsy, trigeminal neuralgia, and bipolar disorder. In a subset of patients, carbamazepine triggers severe cutaneous adverse reactions: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) — immune-mediated blistering reactions involving widespread skin and mucosal membrane detachment, with extensive tissue loss, sepsis risk, and mortality rates of 5-30%. These reactions are not dose-dependent and occur in HLA allele-specific patterns that allow pre-treatment prediction.
Two HLA alleles have been validated as pharmacogenomic biomarkers for carbamazepine SJS/TEN in distinct populations. HLA-B*15:02 is strongly associated with SJS/TEN risk in Han Chinese, Thai, Malaysian, Vietnamese, and other Southeast Asian populations — allele frequency ranging from 5-15% in affected ethnic groups, essentially absent in European populations. HLA-B*15:02 carriers in Asian populations who receive carbamazepine have approximately a 5-10% risk of SJS/TEN, compared to <0.1% in non-carriers. HLA-A*31:01 is associated with carbamazepine hypersensitivity (including SJS/TEN but also milder maculopapular exanthema and drug reaction with eosinophilia and systemic symptoms/DRESS) in Europeans, Japanese, and other populations where HLA-B*15:02 is rare. HLA-A*31:01 frequency is approximately 2-5% in European populations.
The FDA added a warning to carbamazepine in 2007 recommending that patients of Asian ancestry be tested for HLA-B*15:02 before initiating carbamazepine therapy. CPIC provides Level A guidelines for carbamazepine and both HLA-B*15:02 and HLA-A*31:01. Alternative anticonvulsants — lamotrigine, levetiracetam, phenytoin with appropriate HLA consideration, oxcarbazepine — can be prescribed to confirmed HLA risk carriers. The urgency of pre-treatment screening is underscored by the irreversibility of SJS/TEN — once the reaction begins, its course cannot be aborted, and the outcome depends only on early drug cessation and intensive supportive care.
HLA-B*15:02 is the critical allele in Southeast Asian populations. HLA-A*31:01 is the critical allele in European, Japanese, and other populations. Both alleles must be evaluated for complete carbamazepine pharmacogenomic risk assessment across all ancestries.
Commercial tests exist for HLA-B*15:02 alone. What whole genome sequencing adds is comprehensive HLA typing — covering HLA-A*31:01, HLA-B*58:01 (allopurinol), HLA-B*57:01 (abacavir), and all other pharmacogenomically relevant HLA alleles in a single test.
Testing only HLA-B*15:02 misses European carbamazepine hypersensitivity risk from HLA-A*31:01
Commercial point-of-care HLA-B*15:02 tests were developed specifically for Asian patient populations prescribed carbamazepine. When applied in European or mixed-ancestry patient populations, a negative HLA-B*15:02 result is correct but incomplete — it does not address HLA-A*31:01, the primary carbamazepine hypersensitivity allele in Europeans. CPIC recommends testing for HLA-A*31:01 in all non-Asian patients being considered for carbamazepine. A single HLA-B*15:02-only test misses all HLA-A*31:01 risk. Whole genome sequencing performs complete HLA class I typing at 4-digit field resolution, covering all pharmacogenomically relevant HLA alleles simultaneously.
Complete HLA typing is a permanent pharmacogenomic asset covering carbamazepine, allopurinol, abacavir, and future drugs
The pharmacogenomic HLA landscape extends beyond carbamazepine. HLA-B*58:01 predicts allopurinol-induced SJS/TEN (particularly in Han Chinese and Korean populations). HLA-B*57:01 predicts abacavir hypersensitivity. HLA-A*31:01 also predicts oxcarbazepine and phenytoin hypersensitivity in some populations. A patient who requires anti-epileptic or gout medication management may encounter multiple of these prescribing decisions over their lifetime. Complete HLA typing from whole genome sequencing answers all of these questions simultaneously and permanently, with the result stored in the medical record for use at every future prescribing encounter.
Your full DNA (not just a part of it)
Traditional genetic testing looks at narrow sets of genes, missing most parts of your genome. We sequence your full genome — every gene and every region between genes.
Comprehensive insights and specialized reports
Easy to read and with answers you and your doctor can act on. Not a file to interpret — 200+ clinical reports, organized by category.
Your test becomes more valuable every year
Your DNA does not change, but genome science is accelerating. Every month, new variant-disease associations are discovered. We validate these findings and update your reports automatically. Your test becomes more valuable every year.
The results doctors bring to their hardest cases.
Forty years of uncertainty. One test.
A patient had spent decades in the UK healthcare system without a diagnosis. Dante data, accepted by NHS clinical teams at Queen Elizabeth University Hospital Glasgow, identified Noonan Syndrome and a RUNX1 leukemia-associated variant that had gone undetected. After 40 years, they finally had an answer.
A complete read delivers a complete picture.
A patient came to Dante to investigate periodic paralysis. Reading the complete genome identified a concurrent hereditary cardiac finding — Brugada syndrome — that their doctor confirmed with an ECG. The result also explained a family member's unresolved cardiac history. One test. Every answer in it.
Sequenced in 2019. The data worked in 2021.
Jennifer sequenced her genome with Dante two years before her breast cancer diagnosis. When treatment began, Dante's pharmacogenomics data showed her prescribed chemotherapy would cause serious adverse effects. Her doctor selected an alternative — and she started effective treatment from day one.
Every genetic question deserves a complete answer.
Whether you are searching for answers today or protecting your health for tomorrow, a complete read of your entire genome is the only place to start.
It runs in your family. Now you can know if it runs in your genes.
Your genome contains inherited variants associated with medical conditions like cardiac, cancer, and neurological. We read all of them — with the clinical depth to give the result meaning.
Learn more →When traditional lab tests say you're fine. And you know you're not.
Standard diagnostic tests check for a pre-selected set of answers. We sequence your full DNA — including parts that no test was designed to check. If the answer is in your genome, we will help you find it.
Learn more →Your diagnosis may be right. Your treatment plan may be incomplete.
Your genes determine which treatments are most likely to work — and which are not. We give your doctor the tools and insights to inform your treatment plan.
Learn more →You want to know before something forces the question.
Some people don't wait for a diagnosis or a family history to act. Whole genome sequencing gives you the complete genetic picture now — so you and your doctor can make informed decisions before anything becomes urgent.
Learn more →You already took a DNA test. Here's what it couldn't tell you.
Most consumer DNA tests read less than 0.1% of your genome. We read all of it.
Learn more →Clinical-grade results. Chosen by individuals, trusted by doctors for their most complex cases.
Dante Genome Test helped specialists at a UK national acute hospital in the identification of Noonan Syndrome and a rare leukemia-associated genetic variant that had gone undetected. That result changed the medical care of the patient.
Accredited by & published in
Common questions about whole genome sequencing.
What is the difference between whole genome sequencing and a targeted genetic test?
Targeted genetic tests — including standard hereditary cancer panels — read a pre-defined list of known variants in a specific set of genes. They are designed to find what they already know to look for. Whole genome sequencing reads your entire genome: all 6 billion base pairs, every gene, every region between genes. A Mayo Clinic study published in JAMA Oncology found that standard testing guidelines missed more than half of patients with inherited cancer mutations. Genome Test does not have a fixed list.
What will I receive when my results are ready?
Your Dante Genome delivers 200+ physician-ready reports organized by clinical category — hereditary cancer, cardiac conditions, rare diseases, pharmacogenomics, carrier status, and more. Reports are delivered to your secure Genome Manager and are formatted for direct clinical use. Your genome data is permanently retained and re-analyzed automatically as science advances.
What happens if a clinically significant variant is found?
If a pathogenic or likely-pathogenic variant is identified, it will be clearly flagged in your physician-ready report with clinical context, published evidence, and recommended next steps. We recommend sharing any clinically significant finding with your physician or a genetic counselor, who can guide decisions about surveillance, risk reduction, or cascade testing for family members.
How is this different from a consumer DNA test like 23andMe or AncestryDNA?
Consumer DNA tests use genotyping chips that read less than 0.1% of your genome — a tiny pre-selected set of common variants. They are optimized for ancestry and population-level traits, not clinical genetic findings. The Dante Genome Test sequences 100% of your genome at 30X coverage, the same standard used in clinical diagnostic settings. The two tests are not comparable in scope, methodology, or clinical utility.
How long does it take to get results, and how are they delivered?
Your collection kit ships within 48 hours of ordering. Once your sample arrives at our CLIA-certified laboratory, sequencing and analysis takes 6–8 weeks. Results are delivered securely to your Genome Manager, where you can access your reports, share them with your physician, and receive automatic updates as new findings are validated against your genome.
We work with patient advocacy groups worldwide.
Dante Labs works with patient advocacy groups of any size — for Carbamazepine Hypersensitivity — HLA-B*15:02 and other conditions, rare and common. We support groups in any country, including virtual patient advocacy groups.
We can provide customized reports, group discounts, and packages tailored for your members. Please reach out using the form and we'll be in touch within two business days.
- Custom genomic reports for your members
- Group discounts and tailored packages
- Any country — including virtual groups
- Rare and common conditions covered
Message received.
We'll be in touch within 2 business days. To follow up directly: hello@dantelabs.com
One test.
A lifetime of answers.
One kit, sent to your home. Your entire genome sequenced at the clinical standard used for diagnostic decisions. 200+ physician-ready reports delivered to your Genome Manager in 6–8 weeks — permanent and updated as science advances.
Ships within 48 hours · Results in 6–8 weeks
